Seeking Validation.
- Published in:
- Science Translational Medicine, 2012, v. 4, n. 136, p. 1, doi. 10.1126/scitranslmed.3004193
- By:
- Publication type:
- Article
Works matching AU Roblin, David
Results: 8
1
2
The Future of Machine Learning Within Target Identification: Causality, Reversibility, and Druggability.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 115, n. 4, p. 655, doi. 10.1002/cpt.3158
- By:
- Publication type:
- Article
3
The Francis Crick Institute: Scientific Discovery Open to Translation.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 3, p. 133, doi. 10.1007/s40290-016-0143-9
- By:
- Publication type:
- Article
4
Utilizing graph machine learning within drug discovery and development.
- Published in:
- Briefings in Bioinformatics, 2021, v. 22, n. 6, p. 1, doi. 10.1093/bib/bbab159
- By:
- Publication type:
- Article
5
"Sólo nos diferenciamos en haber él hecho segunda de mi primera y yo en imitar su segunda".
- Published in:
- 2016
- By:
- Publication type:
- Literary Criticism
6
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
- Published in:
- Trials, 2017, v. 18, p. 1, doi. 10.1186/s13063-017-1812-z
- By:
- Publication type:
- Article
7
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
- Published in:
- Acta Dermato-Venereologica, 2015, v. 95, n. 5, p. 542, doi. 10.2340/00015555-2047
- By:
- Publication type:
- Article
8
Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article